Imunon (IMNN) Competitors $0.68 -0.01 (-1.44%) (As of 11/20/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort InterestTrends IMNN vs. VVOS, PLUR, ANEB, LVTX, RAPT, CERO, LUMO, OSTX, NXTC, and OKYOShould you be buying Imunon stock or one of its competitors? The main competitors of Imunon include Vivos Therapeutics (VVOS), Pluri (PLUR), Anebulo Pharmaceuticals (ANEB), LAVA Therapeutics (LVTX), RAPT Therapeutics (RAPT), CERo Therapeutics (CERO), Lumos Pharma (LUMO), OS Therapies (OSTX), NextCure (NXTC), and OKYO Pharma (OKYO). These companies are all part of the "medical" sector. Imunon vs. Vivos Therapeutics Pluri Anebulo Pharmaceuticals LAVA Therapeutics RAPT Therapeutics CERo Therapeutics Lumos Pharma OS Therapies NextCure OKYO Pharma Vivos Therapeutics (NASDAQ:VVOS) and Imunon (NASDAQ:IMNN) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their profitability, valuation, risk, media sentiment, analyst recommendations, institutional ownership, community ranking, earnings and dividends. Does the media refer more to VVOS or IMNN? In the previous week, Vivos Therapeutics had 7 more articles in the media than Imunon. MarketBeat recorded 9 mentions for Vivos Therapeutics and 2 mentions for Imunon. Imunon's average media sentiment score of 0.58 beat Vivos Therapeutics' score of 0.27 indicating that Imunon is being referred to more favorably in the news media. Company Overall Sentiment Vivos Therapeutics Neutral Imunon Positive Which has preferable valuation & earnings, VVOS or IMNN? Vivos Therapeutics has higher revenue and earnings than Imunon. Vivos Therapeutics is trading at a lower price-to-earnings ratio than Imunon, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioVivos Therapeutics$13.80M1.01-$13.58M-$5.68-0.51Imunon$500K19.84-$19.51M-$1.89-0.36 Do analysts recommend VVOS or IMNN? Vivos Therapeutics presently has a consensus target price of $6.30, suggesting a potential upside of 117.99%. Imunon has a consensus target price of $12.00, suggesting a potential upside of 1,654.39%. Given Imunon's stronger consensus rating and higher probable upside, analysts plainly believe Imunon is more favorable than Vivos Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Vivos Therapeutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Imunon 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 3.50 Which has more volatility and risk, VVOS or IMNN? Vivos Therapeutics has a beta of 7.71, indicating that its stock price is 671% more volatile than the S&P 500. Comparatively, Imunon has a beta of 2.14, indicating that its stock price is 114% more volatile than the S&P 500. Does the MarketBeat Community believe in VVOS or IMNN? Vivos Therapeutics received 2 more outperform votes than Imunon when rated by MarketBeat users. However, 100.00% of users gave Imunon an outperform vote while only 57.69% of users gave Vivos Therapeutics an outperform vote. CompanyUnderperformOutperformVivos TherapeuticsOutperform Votes1557.69% Underperform Votes1142.31% ImunonOutperform Votes13100.00% Underperform VotesNo Votes Do institutionals and insiders hold more shares of VVOS or IMNN? 26.4% of Vivos Therapeutics shares are owned by institutional investors. Comparatively, 4.5% of Imunon shares are owned by institutional investors. 3.0% of Vivos Therapeutics shares are owned by insiders. Comparatively, 5.0% of Imunon shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. Is VVOS or IMNN more profitable? Imunon has a net margin of 0.00% compared to Vivos Therapeutics' net margin of -86.19%. Imunon's return on equity of -230.05% beat Vivos Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Vivos Therapeutics-86.19% -335.04% -93.58% Imunon N/A -230.05%-128.98% SummaryImunon beats Vivos Therapeutics on 11 of the 19 factors compared between the two stocks. Ad Crypto 101 Media“Sleeping Giant” Crypto Set to Explode…What if I told you there's a crypto that could make Bitcoin look like small change? We're looking at potential returns that could rewrite your financial future. Click here to discover our #1 crypto pick before it's too late Get Imunon News Delivered to You Automatically Sign up to receive the latest news and ratings for IMNN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IMNN vs. The Competition Export to ExcelMetricImunonPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$9.92M$6.41B$5.01B$8.81BDividend YieldN/A8.11%5.21%4.07%P/E Ratio-0.3610.02126.5217.52Price / Sales19.84318.981,203.9085.12Price / CashN/A22.1633.3732.51Price / Book0.485.464.684.68Net Income-$19.51M$152.97M$118.36M$225.62M7 Day Performance-8.40%-4.33%-2.46%-2.04%1 Month Performance-30.59%-8.65%-4.06%0.03%1 Year Performance-26.48%28.53%29.55%24.47% Imunon Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IMNNImunon3.2283 of 5 stars$0.68-1.4%$12.00+1,654.4%-27.6%$9.92M$500,000.00-0.3633VVOSVivos Therapeutics2.4154 of 5 stars$2.89+2.1%$6.30+118.0%-30.0%$13.99M$13.80M0.00160Analyst ForecastPLURPluri0.1625 of 5 stars$5.06+0.2%N/A+4.9%$28.13M$598,000.00-0.84150ANEBAnebulo Pharmaceuticals2.5568 of 5 stars$1.52flat$8.00+426.3%-29.6%$39.42MN/A-5.074Analyst ForecastShort Interest ↓Gap UpLVTXLAVA Therapeutics1.8565 of 5 stars$1.52-1.9%$6.00+294.7%+3.7%$38.53M$7.40M-1.7160Upcoming EarningsRAPTRAPT Therapeutics4.659 of 5 stars$1.07flat$9.50+787.9%-92.4%$37.41M$1.53M-0.3980CEROCERo TherapeuticsN/A$0.25-3.9%N/AN/A$37.40MN/A0.008Gap DownLUMOLumos Pharma3.253 of 5 stars$4.32-0.2%$8.63+99.7%+41.5%$37.36M$2.21M-1.0130OSTXOS TherapiesN/A$1.74-1.7%N/AN/A$36.96MN/A0.00N/ANXTCNextCure4.401 of 5 stars$1.30-0.8%$4.00+207.7%+2.3%$36.41MN/A-0.6390News CoverageOKYOOKYO Pharma2.4353 of 5 stars$1.07+3.9%$7.00+554.2%-39.4%$36.21MN/A0.007Gap Up Related Companies and Tools Related Companies VVOS Competitors PLUR Competitors ANEB Competitors LVTX Competitors RAPT Competitors CERO Competitors LUMO Competitors OSTX Competitors NXTC Competitors OKYO Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:IMNN) was last updated on 11/20/2024 by MarketBeat.com Staff From Our PartnersTesla Execs are Freaking OutIt’s so revolutionary that tech giants like Microsoft, Amazon, and NVIDIA are all lining up to get their hands...Angel Publishing | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredThe smart-money is buying this US$1 lithium stockLithium is getting white-hot once again! And that means well-timed investors who position now in the best n...Resource Stock Digest | Sponsored31 Billionaires Are Loading Up on This SectorWhy are 31 of the world's richest billionaires, like Warren Buffett, Jeff Bezos, the Walton family, and Bill G...InvestorPlace | SponsoredFormer Trump advisor releases terrifying warningGoldman Sachs: 300 Million People Are At Risk The mainstream media are practically ignoring the most import...Wide Moat Research | SponsoredMy favorite credit card just increased its sign-up bonusTired of getting average credit card rewards? This credit card just increased its sign-up bonus to 75,000 bonu...Card Ratings | SponsoredBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Imunon, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Imunon With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
